Nextcure, Inc. (NXTC) — SEC Filings
Nextcure, Inc. (NXTC) — 32 SEC filings. Latest: 8-K (Dec 19, 2025). Includes 16 8-K, 5 10-Q, 3 SC 13G/A.
View Nextcure, Inc. on SEC EDGAR
Overview
Nextcure, Inc. (NXTC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 19, 2025: On December 19, 2025, NextCure, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporated in Delaware with its principal executive offices located in Beltsville, Maryland. No specific events or financial details are provided in the excerpt.
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 2 bearish, 30 neutral. The dominant filing sentiment for Nextcure, Inc. is neutral.
Filing Type Overview
Nextcure, Inc. (NXTC) has filed 16 8-K, 5 10-Q, 1 DEFA14A, 2 DEF 14A, 2 10-K, 3 SC 13G/A, 2 SC 13G, 1 SC 13D/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of NXTC's 26 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$46.4M |
| EPS | -$18.84 |
| Cash Position | $7.3M |
| Total Assets | $39.6M |
| Total Debt | $15.97M |
Key Executives
- Dr. Michael J. Richman
- Dr. G. Steven Burrill
Industry Context
NextCure operates in the biotechnology sector, a highly competitive and capital-intensive industry focused on developing novel therapeutics. Companies in this space often face long development cycles, significant R&D costs, and regulatory hurdles. Success is heavily dependent on clinical trial outcomes and securing substantial funding for ongoing research and commercialization efforts.
Top Tags
sec-filing (4) · 8-k (4) · 10-Q (4) · financials (4) · corporate-governance (3) · filing (3) · executive-compensation (2) · governance (2) · shareholder-vote (2) · proxy-statement (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and Cash Equivalents | $7.3M | Down from $27.7M at Dec 31, 2024, a 73.6% decrease. |
| Marketable Securities | $21.8M | Down from $40.9M at Dec 31, 2024. |
| Total Liquidity | $29.1M | Cash, cash equivalents, and marketable securities as of September 30, 2025, deemed insufficient for one year of operations. |
| Net Loss (9 months) | $46.4M | Increased from $44.1M in the prior year, indicating widening losses. |
| Research and Development Expenses (9 months) | $38.1M | Increased from $32.6M in 2024, driving higher operating losses. |
| Net Cash Used in Operating Activities (9 months) | $41.9M | Increased from $33.8M in 2024, accelerating cash burn. |
| Reverse Stock Split Ratio | 1:12 | Effectuated on July 14, 2025, to maintain Nasdaq compliance. |
| Accumulated Deficit | $426.5M | As of September 30, 2025, reflecting significant historical losses. |
| Commission File Number | 001-38905 | SEC File Number for NextCure, Inc. |
| Film Number | 251120131 | SEC Film Number for the filing |
| Total Assets | $28.01M | As of March 31, 2025 |
| Total Liabilities | $27.90M | As of March 31, 2025 |
| Public Documents | 23 | Number of documents included in the filing. |
| Total Equity | $251.8M | Calculated as Total Assets - Total Liabilities for FY 2024 |
| Net Loss Per Share | $1.73 | For the three months ended September 30, 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Nextcure, Inc. (NXTC)?
Nextcure, Inc. has 32 recent SEC filings from Jan 2024 to Dec 2025, including 16 8-K, 5 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NXTC filings?
Across 32 filings, the sentiment breakdown is: 2 bearish, 30 neutral. The dominant sentiment is neutral.
Where can I find Nextcure, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Nextcure, Inc. (NXTC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Nextcure, Inc.?
Key financial highlights from Nextcure, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NXTC?
The investment thesis for NXTC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Nextcure, Inc.?
Key executives identified across Nextcure, Inc.'s filings include Dr. Michael J. Richman, Dr. G. Steven Burrill.
What are the main risk factors for Nextcure, Inc. stock?
Of NXTC's 26 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Nextcure, Inc.?
Forward guidance and predictions for Nextcure, Inc. are extracted from SEC filings as they are enriched.